Nicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease

Press ReleaseNicox's Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell DiseaseMarch 2nd, 2022 - release at 7:30 am CET Sophia

Related Keywords

United States ,China ,Valbonne ,Provence Alpes Côd Azur ,France ,Paris ,France General ,United Kingdom ,Chinese ,Americans ,Gavin Spencer ,Enregistrement Universel ,Pharma Bio ,Kepler Cheuvreux Damien Choplain ,Sophia Antipolis ,Michele Garufi ,Frank Dellafera ,States Europe ,Lifesci Advisors ,Drug Administration ,Head Of Corporate Development ,Nicox Fera Partnership ,Fera Pharmaceuticals ,Eyevance Pharmaceuticals ,Edison Investment Research Pooya Hemami London ,Garnier Co Dylan Van Haaften Paris ,Sickle Cell ,Euronext Paris ,Orphan Drug Designation ,New Drug Application ,Chief Executive Officer ,Orphan Drug ,Drug Designation ,Cyclooxygenase Inhibiting Nitric Oxide ,Cyclooxygenase Inhibiting Nitric Oxide Donating ,Ocumension Therapeutics ,South East Asian ,Mid Caps ,Investment Research ,Pooya Hemami ,New York ,Damien Choplain ,Vice President ,Chief Business ,Corporate Development ,Sci Advisors ,French Autorit ,Des March ,Nicox ,Partner ,Vera ,Pharmaceuticals ,Btains ,Orphan ,Drug ,Resignation ,Rom ,Aproxcinod ,Treatment ,Pickle ,Fell ,Disease ,